No Data
No Data
Jaguar Health Announces Completed Analysis From Phase 3 OnTarget Trial
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in Its Phase 3 OnTarget Trial for Its Cancer Supportive Care Drug Crofelemer
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients...
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference
No Data
No Data